Physician profile
Charles A Cook
NPI 1699735654
$227,639.64
in general payments reported to CMS, 2019-2025
55 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $27K · 2021: $19K · 2022: $3,907 · 2023: $6,634 · 2024: $52K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Food and Beverage: $2,653 · Travel and Lodging: $1,688 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,625.00 |
| Food and Beverage | $2,653.25 |
| Travel and Lodging | $1,688.03 |
| Education | $138.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $99,758.94 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64,329.19 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $31,914.95 | 2019-2022 | |
| Abbvie INC. | $11,788.82 | 2020-2023 | Linzess, Vraylar |
| Allergan, INC. | $7,043.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,679.38 | 2019-2024 | Farxiga, Airsupra, Wainua |
| Horizon Therapeutics Plc | $1,944.87 | 2019-2023 | Krystexxa |
| Novo Nordisk As | $1,509.13 | 2019 | |
| Novo Nordisk INC | $1,373.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $992.69 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Amarin Pharma, INC. | $454.04 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $401.04 | 2019-2022 | |
| Pfizer INC. | $298.13 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $296.87 | 2022-2025 | Tarpeyo |
| Esperion Therapeutics, INC. | $274.61 | 2020-2023 | Nexletol |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.